Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDT-rGBM: Microsurgical Resection + PDT for Recurrent Glioblastoma
NCT07832448Active, not recruiting
- Start
- Aug 2023
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
Open-label, single-arm trial of hemoporfin in glioblastoma (GBM). Primary endpoint: Rate of tumor recurrence or progression at 24 months. Started Aug 2023; status: active, not recruiting.
02
Drugs
hemoporfin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07832448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07832448.